Linezolid Electrolyte Imbalances
Linezolid primarily causes hyponatremia as its main electrolyte disturbance, though this is not emphasized in FDA labeling, which focuses more on myelosuppression, lactic acidosis, and neuropathy as the major toxicities. 1
Primary Electrolyte Disturbance: Hyponatremia
Hyponatremia occurs in approximately 18% of linezolid-treated patients and can be severe (sodium ≤128 mEq/L) 2. The mechanism appears to be syndrome of inappropriate antidiuretic hormone secretion (SIADH), though this is a relatively recently recognized adverse effect 3.
Risk Factors for Linezolid-Induced Hyponatremia
Two independent risk factors have been identified:
- Elevated C-reactive protein (CRP) before linezolid initiation - Each unit increase in CRP increases odds of hyponatremia by 8% (OR 1.081,95% CI 1.008-1.158) 2
- Concomitant potassium-sparing diuretics - Dramatically increases risk (OR 11.017,95% CI 1.869-64.939) 2
Patients with severe systemic inflammation are at particularly high risk 2.
Monitoring Strategy
Baseline Assessment
- Measure serum sodium, potassium, and CRP before initiating linezolid
- Review medication list specifically for potassium-sparing diuretics (spironolactone, amiloride, triamterene)
- Assess volume status clinically
During Treatment
For patients with elevated CRP or receiving potassium-sparing diuretics: Monitor serum sodium at least twice weekly, or more frequently if symptoms develop 2.
For standard-risk patients: The FDA label does not mandate routine electrolyte monitoring 1, but given the 18% incidence of hyponatremia, checking sodium weekly is prudent, particularly for courses exceeding 2 weeks 4.
Complete blood counts should be monitored weekly per FDA labeling, particularly for treatment >2 weeks 1. This same schedule can incorporate sodium monitoring.
Clinical Presentation and Management
Recognition
Watch for recurrent nausea and vomiting, which may signal either hyponatremia or lactic acidosis (another linezolid toxicity) 1. Patients may also develop confusion, lethargy, or seizures with severe hyponatremia.
Management Approach
If hyponatremia develops:
- Assess severity and symptoms - Sodium ≤128 mEq/L or any symptomatic hyponatremia requires immediate attention
- Confirm SIADH - Check paired serum and urine osmolality and sodium; SIADH shows inappropriately concentrated urine (>100 mOsm/kg) with low serum osmolality and elevated urine sodium (>40 mEq/L) in euvolemic patients 3
- Consider discontinuing linezolid - Hyponatremia resolves after stopping the drug 3
- Initiate fluid restriction as first-line for SIADH if linezolid must be continued
- For severe symptomatic hyponatremia - Use hypertonic saline with careful correction rates to avoid osmotic demyelination syndrome
Critical Caveats
The FDA label does not specifically warn about hyponatremia or require sodium monitoring 1, making this an under-recognized toxicity. The label emphasizes myelosuppression, lactic acidosis, peripheral/optic neuropathy, and serotonin syndrome instead.
Avoid potassium-sparing diuretics during linezolid therapy when possible, given the 11-fold increased risk of hyponatremia 2.
Duration matters - Linezolid is FDA-approved for maximum 28 days of treatment 1. Extended courses increase risks of neuropathy and likely hyponatremia as well.
Lactic acidosis overlap - Patients with recurrent nausea/vomiting need evaluation for both hyponatremia AND lactic acidosis (check bicarbonate, lactate, and sodium simultaneously) 1.